Bicadex Mechanism of Action

Pharmacology: Pharmacodynamics: Bicalutamide is a nonsteroidal antiandrogen, devoid of other endocrine activity. It binds to androgen receptors without activating gene expression and thus, inhibits the androgen stimulus. Regression of prostatic tumors results from this inhibition. Clinically, discontinuation of bicalutamide can result in antiandrogen withdrawal syndrome in a subset of patients.
Bicalutamide is a racemate with its antiandrogenic activity being almost exclusively in the (R)-enantiomer.
Pharmacokinetics: Bicalutamide is well absorbed following oral administration. There is no evidence of any clinically relevant effect of food on bioavailability.
The (S)-enantiomer is rapidly cleared relative to the (R)-enantiomer, the latter having a plasma elimination t_½ of about 1 week.
On daily administration of bicalutamide, the (R)-enantiomer accumulates about 10-fold in plasma as a consequence of its long t_½.
Steady-state plasma concentrations of the (R)-enantiomer of approximately 9 mcg/mL are observed during daily administration of bicalutamide 50 mg doses. At steady state, the predominantly active (R)-enantiomer accounts for 99% of the total circulating enantiomers.
The pharmacokinetics of the (R)-enantiomer are unaffected by age, renal impairment or mild to moderate hepatic impairment. There is evidence that for subjects with severe hepatic impairment, the (R)-enantiomer is more slowly eliminated from plasma.
Bicalutamide is highly protein bound (racemate 96%, R-bicalutamide 99.6%) and extensively metabolized (via oxidation and glucuronidation). Its metabolites are eliminated via the kidneys and bile in approximately equal proportions. After excretion in the bile, hydrolysis of the glucuronides comes to existence. In the urine, scarcely altered bicalutamide is found.
Toxicology: Preclinical Safety Data: Bicalutamide is a potent antiandrogen and a mixed function oxidase enzyme inducer in animals. Target organ changes, including tumor induction in animals, are related to these activities. None of the findings in the preclinical testing is considered to have relevance to the treatment of advance prostate cancer patients.